757942-75-9

Upstream product

• 640897-02-5 (1S,4S)-6-difluoromethylenyl-2-(4‘-methoxybenzyl)-2-azabicyclo[2.2.1]heptan-3-one 
• 757942-74-8 (E/Z)-(1S,4S)-6-(1‘-fluoro-1‘-phenylsulfonyl)methylenyl-2-(4‘-methoxybenzyl)-2-azabicyclo[2.2.2]heptan-3-one 

Relevant academic research and scientific papers

ORNITHINE AMINOTRANSFERASE INHIBITION WITH GABA ANALOGUES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA

Therapeutic methods relating to the use of GABA-AT inhibitor compounds for the treatment of hepatocellular carcinoma.

Conformationally-restricted vigabatrin analogs as irreversible and reversible inhibitors of γ-aminobutyric acid aminotransferase

Compounds that inhibit γ-aminobutyric acid aminotransferase exhibit anticonvulsant activity; vigabatrin is a known irreversible inhibitor of this enzyme and anticonvulsant drug. Conformationally-restricted, five-membered- and six-membered-ring vigabatrin analogs were synthesized and tested as inhibitors of γ-aminobutyric acid aminotransferase. Two monofluorinated compounds, 4 and 5, are time-dependent inhibitors of the enzyme, and their potencies are comparable to that of vigabatrin. Compounds 6 and 7 are weak reversible inhibitors.

Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase

(1S, 3S)-3-Amino-4-difluoromethylene-1-cyclopentanoic acid illustrates a novel class of compounds as potent irreversible inhibitors of γ-aminobutyric acid aminotransferase (GABA-AT). The corresponding monofluoro-substituted compounds also are potent time-